PaigePaiges Page

Originally posted in Cystic Fibrosis News From Medical News Today

Kalydeco has been approved by the Food And Drug Administration (FDA) to treat a vicious type of Cystic Fibrosis (CF). CF is a deadly recessive disease which targets the lungs, but can also harm the liver, pancreas, and intestine. It occurs from the unusual transport of chloride and sodium across the epithelium, causing mucus buildup in the lungs, and thick secretions…

Originally posted in Cystic Fibrosis News From Medical News Today

The lung clearance index (LCI) is a sensitive non-invasive marker of early lung disease in young children with cystic fibrosis (CF), according to a new study from Australian researchers…

Originally posted in Cystic Fibrosis News From Medical News Today

According to a new Australian study published online before he print publication in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine, the lung clearance index (LCI) is a sensitive, non-invasive marker of early lung disease in young children with cystic fibrosis (CF)…

Originally posted in Cystic Fibrosis News From Medical News Today

Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment’s efficacy and good safety profile, the convenience and ease of administration of mannitol treatment may improve adherence with therapy in these patients…

Originally posted in Cystic Fibrosis News From Medical News Today

A new study found that the combination of inhaled dry powder mannitol with standard therapy for cystic fibrosis resulted in maintained improvement in lung function for 12 months. In addition to being effective and safe, the easy administration of the treatment might help enhance adherence with treatment in individuals suffering with the condition…

Originally posted in Cystic Fibrosis News From Medical News Today

Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment’s efficacy and good safety profile, the convenience and ease of administration of mannitol treatment may improve adherence with therapy in these patients…

Originally posted in Cystic Fibrosis News From Medical News Today

Scientists at Queen’s University Belfast have begun work into improving the lives of thousands of Cystic Fibrosis sufferers thanks to the award of a 1.74 million pound US-Ireland Research and Development Partnership grant…

Mpex Pharmaceuticals, Inc. during the JP Morgan 29th Annual Healthcare Conference, announced that it has initiated its Phase 3 clinical trial program with Aeroquinâ„¢ (MP-376) for the treatment of pulmonary infections in patients with cystic fibrosis (CF)…

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced the top-line results from its second Phase 3 clinical trial, TIGER-2, with denufosol tetrasodium for the treatment of cystic fibrosis (CF)…

A team of Johns Hopkins Children’s Center researchers has discovered that a protein involved in cystic fibrosis (CF) also regulates inflammation and cell death in emphysema and may be responsible for other chronic lung diseases…